acetylleucyl-leucyl-norleucinal has been researched along with Long QT Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cen, Z; Fang, P; Lian, J; Liu, N; Lou, K; Qian, H; Shen, T; Wang, Y; Zhou, J | 1 |
| Chung, Y; Liew, R; Mehta, A; Ramachandra, CJ; Sequiera, GL; Sheng, J; Shim, W; Sudibyo, Y; Tan, TH; Wong, KY; Wong, P | 1 |
| Gong, Q; Keeney, DR; Molinari, M; Zhou, Z | 1 |
3 other study(ies) available for acetylleucyl-leucyl-norleucinal and Long QT Syndrome
| Article | Year |
|---|---|
The role and mechanism of chaperones Calnexin/Calreticulin in which ALLN selectively rescues the trafficking defective of HERG-A561V mutation.
Topics: Calnexin; Calreticulin; ERG1 Potassium Channel; HEK293 Cells; Humans; Leupeptins; Long QT Syndrome; Molecular Chaperones; Mutation; Patch-Clamp Techniques; Propranolol; Protein Transport | 2018 |
Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.
Topics: Animals; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Induced Pluripotent Stem Cells; Leupeptins; Long QT Syndrome; Male; Mice; Mutation; Myocytes, Cardiac; Phenotype; Protein Transport | 2014 |
Degradation of trafficking-defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway.
Topics: Acetylcysteine; Alkaloids; Blotting, Western; Cell Line; Cell Membrane; Cysteine Proteinase Inhibitors; Cytosol; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Enzyme Inhibitors; Glycosylation; Green Fluorescent Proteins; Humans; Immunoprecipitation; Leupeptins; Long QT Syndrome; Mutation; Potassium Channels; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Ribonucleases; Subcellular Fractions; Time Factors; Transfection; Ubiquitin | 2005 |